Aim immunotech announces open enrollment for phase 1b/2 study evaluating ampligen® (rintatolimod) in combination with astrazeneca's imfinzi® (durvalumab) for the treatment of pancreatic cancer

First enrollment and first subject dosing expected soon at erasmus medical center in rotterdam, netherlands management discusses the announcement and what this means here: video ocala, fla., jan. 10, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced that enrollment is open at erasmus medical center (“erasmus mc”) in a phase 1b/2 clinical trial combining aim's ampligen® (rintatolimod) with astrazeneca's anti-pd-l1 immune checkpoint inhibitor imfinzi® (durvalumab) for the treatment of pancreatic cancer (the “duripanc study”).
AIM Ratings Summary
AIM Quant Ranking